Compare Verizon Communications Inc (VZ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verizon Communications Inc vs GeneDx Holdings Corp — how do they compare? Verizon Communications Inc trades at $41.85 (market cap $192.57B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Verizon Communications Inc is far larger — about 95.3× GeneDx Holdings Corp's market cap, and Verizon Communications Inc pays a 6.11% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Verizon Communications Inc for 109 Days and GeneDx Holdings Corp for 19 Days on average.
| VZ | WGS | |
|---|---|---|
Market Cap | $192.57B | $2.02B |
Volume | 20,940,094 | 734,640 |
Sector | Media | Health |
52-Week High | $51.45 | $167.51 |
52-Week Low | $38.40 | $34.51 |
Typical Hold Time | 109 Days | 19 Days |
Enterprise Value | $379.28B | $2.05B |
Dividend Yield | 6.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Verizon (VZ) trades at $41.65, down 9% today, with bearish technical signals but solid fundamentals. The stock shows consistent earnings beats (Q4 2025-Q2 2026) and maintains strong cash flow ($37.1B operating cash flow in 2025). Recent news highlights Verizon's joint venture with AT&T and T-Mobile to expand coverage and the election of Charles Phillips to the board (GlobeNewsWire, September 29, 2026).
Outlook: Attractive for income investors with a 6.8% dividend yield and stable cash flow, but high debt ($144B total debt) and competitive pressures pose risks. Analyst consensus price target of $48.17 suggests 16% upside, though technical indicators remain bearish near-term.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
